PubMed Health⌕ Search

Biomedical subjects

F Marchesi

Publications and source records attributed to F Marchesi.

22 records · Page 2Linked to original sources
PubMedDate not supplied

Experience with a drug formulary in a large Italian city hospital.

The preparation and distribution of a drug formulary, providing some 377 pharmacological entities together with significant general information, in a large city hospital, enabled the collection of data on the pattern of drug use in this setting. Out of the 377 selected drugs, 27 were never used in the course of one year: most notable among these were the cephalosporin cephalothin, the antifungal griseofulvin, piperazine and the leading anti-H1-blocker terfenadine. Thirteen pharmaceutical preparations were used in over 50,000 doses; among these were the amiloride + hydrochlorothiazide combination, co-trimoxazole and lorazepam. Examination of specific drug series, e.g. of cephalosporins, showed a clear preference for the longer acting ceftriaxone versus a minor use for oral agents, e.g. cefadroxil. There was a wide choice of cardiovascular agents and a relative stability in the preference for major and minor antipsychotics. Outside of the formulary list, only a small number of preparations were requested, among these some traditional analgesic combinations and some extractive products. The provision of a hospital formulary may, in some way, modify drug choice in the hospital, although some established patterns of use are difficult to change. On the other hand, some interesting information was provided on the criteria of choice of hospital physicians.

Formularies, Hospital as Topic↗
PubMedDate not supplied

[Indications for recombinant growth hormone (rhGH) treatment in kidney diseases].

Growth retardation is one of the major problem in children with chronic and terminal renal failure. The growth hormone-insulin-like growth factor axis is altered in uraemia, resulting in peripheral resistance. This insensitivity seems to be overcome in an experimental study by supraphysiological doses of recombinant human growth hormone (rhGH). Several clinical studies have confirmed that rhGH increases growth velocity in children with chronic renal failure with and without dialysis and after renal transplant, without significant side-effects. The improvement of growth is more marked in prepubertal patients and during the first year of rhGH treatment. Also in our experience prepubertal children showed an increase of height standard deviation score and growth velocity during rhGH treatment; the pubertal patients failed to improve their statural growth. GH, as the prototype of an anabolic hormone, has also great potential in improving catabolic conditions of various origin, particularly those due to renal failure. RhGH can improve nitrogen balance and the nutritional parameters with an increase of muscle mass and a decrease of fat mass. Prospectively, rhGH could be utilized to improve the hypercatabolic condition of acute renal failure. The following analysis will discuss the recent studies employing rhGH in renal diseases and will attempt to give some guide lines to rhGH treatment in these illnesses.

Adolescent↗